Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

Dual eligible patients more likely to be hospitalized than Medicare beneficiaries: AHRQ

Americans who were eligible for coverage under both Medicare and Medicaid in 2008 were hospitalized for bed sores, asthma and diabetes at more than twice the rate of other Medicare beneficiaries, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

27 Sep 2010

ProtAffin presents impressive efficacy data for PA401 in COPD

ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today presents compelling preclinical data in chronic obstructive pulmonary disease (COPD) for its lead product PA401 at the European Respiratory Society Congress in Barcelona, Spain. This conference is the largest gathering of scientists and clinicians in the respiratory community in the world. The Oral Presentation will be made in the session "Pre-clinical models of airways disease".

21 Sep 2010

Tiotropium bromide shows potential as an alternative asthma treatment

A drug commonly used for the treatment of chronic obstructive pulmonary disease (COPD) successfully treats adults whose asthma is not well-controlled on low doses of inhaled corticosteroids, reported researchers supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

20 Sep 2010

HealthWyse, Cardiocom partner to integrate patient information into clinical software

HealthWyse, a leading provider of home health and hospice software and services, announced today that it has partnered with Cardiocom, a leader in home telehealth solutions, to seamlessly integrate patient information into HealthWyse's clinical software.

13 Sep 2010

Forest files response to FDA Complete Response Letter for roflumilast NDA

Forest Laboratories, Inc. today announced that it has filed a response to the U.S. Food & Drug Administration (FDA) addressing topics raised in the complete response letter regarding the New Drug Application (NDA) for roflumilast. Forest licenses roflumilast from Nycomed, which submitted the original NDA.

13 Sep 2010

Research finds immune system mechanism to minimize collateral damage

A study published today in the journal Science shows how our bodies try to minimise potential 'collateral damage' caused by our immune system when fighting infection. The research may also provide new clues to why cigarette smoke is a significant risk factor for developing diseases of the lung such as chronic bronchitis and emphysema.

3 Sep 2010

Californians recognized for contributing to plasma protein lifesaving therapies

This month, Californians are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that makes the creation of these unique therapies possible.

3 Sep 2010

Cigarette smoke inhibits LTA4H enzyme, regulates body's response to inflammation: Study

Cigarette smoke shuts off a key enzyme in airways that regulates the body's response to inflammation, according to findings from the University of Alabama at Birmingham published online today at Science Express.

3 Sep 2010

Pharmacor 2010 findings predict COPD drug market rise to $13 billion in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2019, an expanding aging population and increases in diagnosis and drug treatment will fuel steady 4.6 percent annual growth in the chronic obstructive pulmonary disease (COPD) drug market.

2 Sep 2010

Lotus Pharmaceuticals initiates R-Bambuterol Clinical Trial I on-schedule

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China, announced today that it has entered R-Bambuterol Clinical Trial I on-schedule and is on-track to complete in six months. The studies will evaluate the safety and tolerability of the new drug as well as the biological activity by measuring responses in healthy volunteers.

26 Aug 2010

Angeion Corporation 2010 third quarter revenue increases to $7.1 million

Angeion Corporation today reported results for its fiscal third quarter ended July 31, 2010.

26 Aug 2010

Ingen’s products fill key void for Mountainside Medical Equipment

Ingen Technologies, Inc.,an emerging medical device manufacturer developing innovative proprietary solutions for the $8 billion respiratory market, today announced that its products have filled a key void for Mountainside Medical Equipment (www.mountainside-medical.com), a veteran-owned worldwide distributor of medical supplies based in Upstate New York.

24 Aug 2010

Tips for management of COPD

What is the fourth leading cause of death in the United States? Many would be surprised to learn that chronic obstructive pulmonary disease (COPD) is, and the number of people with COPD is increasing. According to the COPD Foundation, more than 12 million Americans are currently diagnosed with COPD and an additional 12 million may not realize their shortness of breath and coughing are in fact symptoms of this debilitating condition.

20 Aug 2010

Even low-level exposure to cigarette smoke affects gene function in lungs

Casual smokers may think that smoking a few cigarettes a week is "no big deal." But according to new research from physician-scientists at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, having an infrequent smoke, or being exposed to secondhand smoke, may be doing more harm than people may think. The findings may further support public smoking bans, say the authors.

20 Aug 2010

Researcher identifies immune system's ability to protect body against lung cancer

A Michigan State University researcher is analyzing the immune system's own ability to protect the body against lung cancer.The results of the work by Alison Bauer, an assistant professor of pathobiology and diagnostic investigation in the College of Veterinary Medicine, are expected to provide new approaches to prevent, identify and treat lung cancer.

18 Aug 2010

Treatment for diabetics cost U.S. hospitals 25% more than stays for non-diabetics

U.S. hospitals spent $83 billion in 2008 caring for people with diabetes, according to the latest News and Numbers from the Agency for Healthcare Research and Quality. In that year, nearly one of every five hospitalizations involved a person with diabetes.

16 Aug 2010

Acoustic cardiography improves diagnostic accuracy in acute heart failure

It allows them to hear the S3, an abnormal third sound in the heart's rhythm strongly associated with cardiac disease and heart failure. However, the low-frequency, low-pitch sound is notoriously very difficult to hear with a stethoscope alone.It allows them to hear the S3, an abnormal third sound in the heart's rhythm strongly associated with cardiac disease and heart failure. However, the low-frequency, low-pitch sound is notoriously very difficult to hear with a stethoscope alone.

11 Aug 2010

Clinical Data first-quarter gross revenue increases 52% to $6.2 million

Clinical Data, Inc. today announced operational and financial results for the first quarter ended June 30, 2010, noting key accomplishments including the acceptance of the Company's new drug application (NDA) for vilazodone by the U.S. Food and Drug Administration (FDA) and the successful completion of a public offering .

9 Aug 2010

Research Roundups: Expanding Medicaid; More spending doesn't reduce mortality; Colonoscopy cost effectiveness; Kids, asthma and access to care

Health Affairs: Little Evidence Of Correlation Between Growth In Health Care Spending And Reduced Mortality - This study examines differences in hospital mortality and cost between 2000 and 2004 for patients at 122 U.S. hospitals, with seven common medical diagnoses: acute myocardial infarction, chronic obstructive pulmonary disease, community-acquired pneumonia, congestive heart failure, cerebrovascular accident (also called ischemic stroke), sepsis, or urinary tract infection.

7 Aug 2010

FDA approves N30 Pharma's NDA for N6022 GSNOR

N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD).

3 Aug 2010